Semaglutide Injection By Marshall Healthcare

Semaglutide 2.4 mg injection is a prescription medication primarily used for chronic weight management in adults and adolescents (12 years and older). It's typically prescribed alongside a reduced-calorie diet and increased physical activity.
Here's a detailed description:

Brand Name: The most well-known brand name for semaglutide 2.4 mg injection is WegovyA A A AR. Other semaglutide products (like OzempicA A A A A A A AR and RybelsusA A A A A A A AR) are available in different dosages and primarily indicated for type 2 diabetes management, though they may be prescribed off-label for weight loss.

Mechanism of Action:
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the effects of the natural GLP-1 hormone in the body, which has multiple actions related to glucose control and appetite regulation:
Increases insulin secretion: It stimulates the pancreas to release more insulin in a glucose-dependent manner, helping to lower blood sugar levels.
Lowers glucagon secretion: It reduces the release of glucagon, a hormone that raises blood sugar.

Slows gastric emptying: This helps you feel fuller for longer and reduces the rate at which glucose enters the bloodstream after a meal.
Reduces appetite and food cravings: It interacts with GLP-1 receptors in the brain (specifically the hypothalamus) to decrease hunger, reduce food cravings, and enhance feelings of satiety. This leads to a reduction in overall calorie intake.

Indications:
Weight management: For adults with an initial Body Mass Index (BMI) of A A A AcA A A A A A A AY30kg/m
2
(obesity) or A A A AcA A A A A A A AY27kg/m
2
(overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, dyslipidemia). Also for adolescents aged 12 and older with obesity.
Cardiovascular risk reduction: It's also used to lower the risk of major adverse cardiovascular events (like heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease, or in individuals who are overweight or obese with heart disease.

Kidney disease: For lowering the risk of worsening kidney disease, end-stage kidney disease, and death caused by heart or blood vessel disease in patients with type 2 diabetes and chronic kidney disease.
Administration:

Semaglutide 2.4 mg is administered as a subcutaneous injection (under the skin) once weekly.
It comes in a pre-filled pen.
Common injection sites include the abdomen, thigh, or upper arm. It's important to rotate injection sites each week within the same body region.

It can be taken with or without food, on the same day each week.
The dosage is typically started low (e.g., 0.25 mg weekly) and gradually increased over several weeks to reach the maintenance dose of 2.4 mg, to help minimize gastrointestinal side effects.
Common Side Effects:
The most common side effects are often gastrointestinal in nature and tend to lessen over time:
Nausea
Diarrhea
Vomiting
Constipation
Stomach (abdominal) pain
Headache

Tiredness (fatigue)
Upset stomach

Dizziness

Serious Side Effects (Less Common):

Pancreatitis (inflammation of the pancreas)

Gallbladder problems (e.g., gallstones)

Hypoglycemia (low blood sugar), especially when used with other diabetes medications like insulin or sulfonylureas.

Kidney problems (kidney failure)

Severe stomach problems

Serious allergic reactions (e.g., rash, swelling of face/tongue/throat, trouble breathing)

Changes in vision (especially in people with type 2 diabetes and a history of diabetic retinopathy)

Increased heart rate

Risk of thyroid C-cell tumors (seen in rodent studies; human relevance unknown. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2).

Depression or thoughts of suicide (monitor for changes in mood/behavior)

Food or liquid getting into the lungs during surgery or procedures requiring deep sedation due to delayed gastric emptying.